Table 3.
Differences in patient characteristics who developed grade 3 or higher thrombocytopenia according to whether toxicity was immune-related
| Variable | Description | 1:Likely/possible immune toxicity (n = 18) | 2:Unlikely immune toxicity (n = 71) | Total (n = 89) | p-value |
|---|---|---|---|---|---|
| Age |
Median [IQR] (min, max) |
57.8 [50, 68] (35.7, 77.1) |
60.1 [52.5, 69.2] (19.4, 85.1) |
59.7 [52.5, 68] (19.4, 85.1) |
0.7671 |
| Race | White | 18 (100%) | 61 (85.9%) | 79 (88.8%) | 0.2029 |
| Non-white | 0 (0%) | 10 (14.1%) | 10 (11.2%) | ||
| Sex | Male | 10 (55.6%) | 41 (57.7%) | 51 (57.3%) | 1.0000 |
| Female | 8 (44.4%) | 30 (42.3%) | 38 (42.7%) | ||
| Smoking status | No | 12 (66.7%) | 35 (49.3%) | 47 (52.8%) | 0.2904 |
| Yes | 6 (33.3%) | 36 (50.7%) | 42 (47.2%) | ||
| Type of immunotherapy | PD-1/L1 | 8 (44.4%) | 54 (76.1%) | 62 (69.7%) | 0.0591 |
| CTLA-4 | 4 (22.2%) | 9 (12.7%) | 13 (14.6%) | ||
| Combination PD-1/CTLA-4 | 4 (22.2%) | 5 (7%) | 9 (10.1%) | ||
| Other | 2 (11.1%)* | 3 (4.2%)† | 5 (5.6%) | ||
| Cancer type | Melanoma | 9 (50%) | 14 (19.7%) | 23 (25.8%) | 0.0752 |
| NSCLC + SCLC | 1 (5.6%) | 14 (19.7%) | 15 (16.9%) | ||
| RCC | 0 (0%) | 3 (4.2%) | 3 (3.4%) | ||
| Head and neck | 1 (5.6%) | 2 (2.8%) | 3 (3.4%) | ||
| Other | 7 (38.9%) | 38 (53.5%) | 45 (50.6%) | ||
| BMI |
Median [IQR] (min, max) |
missing = 0 28.9 [24.9, 32.3] (17, 47.1) |
missing = 2 29.1 [25.6, 33.8] (19.1, 50.2) |
missing = 2 29.1 [24.9, 33.5] (17, 50.2) |
0.7060 |
| Line of therapy | Missing | 1 | 0 | 1 | 0.9394 |
| 1 | 6 (35.3%) | 21 (29.6%) | 27 (30.7%) | ||
| 2 | 4 (23.5%) | 17 (23.9%) | 21 (23.9%) | ||
| > = 3 | 7 (41.2%) | 33 (46.5%) | 40 (45.5%) |
*Pembrolizumab + acalabrutinib (n = 2). †Pembrolizumab + BMS-986156, a glucocorticoid-induced tumor necrosis factor receptor-related protein antagonist monoclonal antibody (n = 1), pembrolizumab + acalabrutinib (n = 1), nivolumab + cisplatin (n = 1)